Open AccessPOTENTIAL OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN THE TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND CORONARY HEART DISEASE
Author(s) -
А. Г. Евдокимова,
В В Евдокимов
Publication year - 2013
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2013-1-80-87
Subject(s) - enalapril , medicine , angiotensin converting enzyme , cardiology , heart failure , nebivolol , hydrochlorothiazide , ace inhibitor , coronary heart disease , blood pressure
For the last 30 years, angiotensin-converting enzyme (ACE) inhibitors have been playing a key role in the management of arterial hypertension (AH) and related cardiovascular disease. This review discusses the mechanisms of action and organo-protective effects of ACE inhibitors. Enalapril is the most extensively studied and widely used in the international clinical practice ACE inhibitor. The authors analyse the results of the studies on enalapril therapy in AH, coronary heart disease (CHD), chronic heart failure, metabolic syndrome, and postmenopause. It has been demonstrated that the combination antihypertensive therapy with a β-adrenoblocker nebivolol, enalapril, and hydrochlorothiazide (such as Berlipril® Plus) is safe and effective in patients with AH and CHD.